Cargando…

Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection

PURPOSE: To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection procedures. METHODS: Seventy eyes of 70 patients who had not previously undergone intravitreal anti-vascular endothelial growth factor therapy were included in this study. Thirty-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Güler, Mete, Bilgin, Burak, Çapkın, Musa, Şimşek, Ali, Bilak, Şemsettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Ophthalmological Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446560/
https://www.ncbi.nlm.nih.gov/pubmed/26028948
http://dx.doi.org/10.3341/kjo.2015.29.3.190
_version_ 1782373452494143488
author Güler, Mete
Bilgin, Burak
Çapkın, Musa
Şimşek, Ali
Bilak, Şemsettin
author_facet Güler, Mete
Bilgin, Burak
Çapkın, Musa
Şimşek, Ali
Bilak, Şemsettin
author_sort Güler, Mete
collection PubMed
description PURPOSE: To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection procedures. METHODS: Seventy eyes of 70 patients who had not previously undergone intravitreal anti-vascular endothelial growth factor therapy were included in this study. Thirty-five patients received ranibizumab and 35 patients received bevacizumab. The diagnoses of the patients were: 27 age related macular degeneration, 15 diabetic macular edema, 9 diabetic vitreous hemorrhage, 6 central retinal vein occlusion, 11 branch retinal vein occlusion and 2 central serous chorioretinopathy. Bevacizumab (1.25 mg/0.05 mL) was injected into the vitreous cavity using a 27-gauge needle, and ranibizumab (0.5 mg/0.05 mL) was injected with 30-gauge needle. Patients were asked just after the injection to rate their perceived pain during the injection using the visual analogue scale (VAS) of 0 (no pain) to 10 (unbearable/worst pain). The average of these scores was used as the primary outcome. RESULTS: The VAS pain scores in the ranibizumab and bevacizumab groups were 1.06 ± 0.91 (range, 0 to 3) and 1.94 ± 1.55 (range, 0 to 7), respectively, a significant difference (p = 0.005). Patients <65 and ≥65 years of age in both the ranibizumab and bevacizumab groups were then compared. For patients <65, there was a significant difference in the average VAS pain scores between groups (p = 0.003). However, for patients ≥65 years, there was not a significant difference in the average VAS pain scores between groups (p = 0.238). Female and male patients in both ranibizumab and bevacizumab groups were also compared. For female patients, there was a significant difference in the average VAS pain scores between groups (p = 0.016), although not for male patients (p = 0.078). CONCLUSIONS: Thirty-gauge intravitreal injection is more comfortable than 27-gauge injection. Injection of bevacizumab with 30-gauge needle syringes may be more tolerable for patients.
format Online
Article
Text
id pubmed-4446560
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Ophthalmological Society
record_format MEDLINE/PubMed
spelling pubmed-44465602015-06-01 Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection Güler, Mete Bilgin, Burak Çapkın, Musa Şimşek, Ali Bilak, Şemsettin Korean J Ophthalmol Original Article PURPOSE: To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection procedures. METHODS: Seventy eyes of 70 patients who had not previously undergone intravitreal anti-vascular endothelial growth factor therapy were included in this study. Thirty-five patients received ranibizumab and 35 patients received bevacizumab. The diagnoses of the patients were: 27 age related macular degeneration, 15 diabetic macular edema, 9 diabetic vitreous hemorrhage, 6 central retinal vein occlusion, 11 branch retinal vein occlusion and 2 central serous chorioretinopathy. Bevacizumab (1.25 mg/0.05 mL) was injected into the vitreous cavity using a 27-gauge needle, and ranibizumab (0.5 mg/0.05 mL) was injected with 30-gauge needle. Patients were asked just after the injection to rate their perceived pain during the injection using the visual analogue scale (VAS) of 0 (no pain) to 10 (unbearable/worst pain). The average of these scores was used as the primary outcome. RESULTS: The VAS pain scores in the ranibizumab and bevacizumab groups were 1.06 ± 0.91 (range, 0 to 3) and 1.94 ± 1.55 (range, 0 to 7), respectively, a significant difference (p = 0.005). Patients <65 and ≥65 years of age in both the ranibizumab and bevacizumab groups were then compared. For patients <65, there was a significant difference in the average VAS pain scores between groups (p = 0.003). However, for patients ≥65 years, there was not a significant difference in the average VAS pain scores between groups (p = 0.238). Female and male patients in both ranibizumab and bevacizumab groups were also compared. For female patients, there was a significant difference in the average VAS pain scores between groups (p = 0.016), although not for male patients (p = 0.078). CONCLUSIONS: Thirty-gauge intravitreal injection is more comfortable than 27-gauge injection. Injection of bevacizumab with 30-gauge needle syringes may be more tolerable for patients. The Korean Ophthalmological Society 2015-06 2015-05-20 /pmc/articles/PMC4446560/ /pubmed/26028948 http://dx.doi.org/10.3341/kjo.2015.29.3.190 Text en © 2015 The Korean Ophthalmological Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Güler, Mete
Bilgin, Burak
Çapkın, Musa
Şimşek, Ali
Bilak, Şemsettin
Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title_full Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title_fullStr Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title_full_unstemmed Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title_short Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
title_sort assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446560/
https://www.ncbi.nlm.nih.gov/pubmed/26028948
http://dx.doi.org/10.3341/kjo.2015.29.3.190
work_keys_str_mv AT gulermete assessmentofpatientpainexperienceduringintravitreal27gaugebevacizumaband30gaugeranibizumabinjection
AT bilginburak assessmentofpatientpainexperienceduringintravitreal27gaugebevacizumaband30gaugeranibizumabinjection
AT capkınmusa assessmentofpatientpainexperienceduringintravitreal27gaugebevacizumaband30gaugeranibizumabinjection
AT simsekali assessmentofpatientpainexperienceduringintravitreal27gaugebevacizumaband30gaugeranibizumabinjection
AT bilaksemsettin assessmentofpatientpainexperienceduringintravitreal27gaugebevacizumaband30gaugeranibizumabinjection